Oncotarget · 2017 · 57 citations · 18 references
MedicineOncologyPharmacologyMetastasisMolecular OncologyPrecision MedicineCancer BiomarkersCancer ProgressionColorectal CancerMalignant NeoplasmsMetastatic Cancer ManagementMolecular Tumor ProfilingCancer Metastasis BiomarkersCetuximab TherapyColorectal Cancer BiomarkersMicrorna Function In CancerMicrorna In CancerMicrorna Prognostic MarkersPost Hoc AnalysisTumor-specific Biomarkers
// Siân Pugh 1, * , Raphaële Thiébaut 2, * , John Bridgewater 3, * , Marie-Lise Grisoni 2 , Karwan Moutasim 4 , Francis Rousseau 2 , Gareth J. Thomas 4 , Gareth Griffiths 5 , François Liebaert 2 , John Primrose 1, * and Pierre Laurent-Puig 6, 7, * 1 University Surgery, Cancer Sciences, University of Southampton, Southampton, United Kingdom 2 IntegraGen SA, Evry, France 3 UCL Cancer Institute, London, United Kingdom 4 Cancer Sciences Division, University of Southampton, Southampton, United Kingdom 5 Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom 6 UMR-S1147, University Paris Descartes, Paris, France 7 Assistance Publique-Hôpitaux de Paris, Hôpital Georges Pompidou, Paris, France * These authors have contributed equally to this work Correspondence to: Raphaële Thiébaut, email: raphaele.thiebaut@integragen.com Keywords: metastatic colorectal cancer, biomarker, miR-31-3p, anti-EGFR, cetuximab Received: March 22, 2017     Accepted: August 27, 2017     Published: September 27, 2017 ABSTRACT Background : High miR-31-3p expression is associated with inferior outcomes in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-EGFR therapy. This study evaluated miR-31-3p expression in patients with operable colorectal liver metastases (LM) enrolled in the New EPOC study. Methods : MiR-31-3p expression was measured in primary tumors (PT) from 149 KRAS WT patients including 71 receiving chemotherapy alone (CT) and 78 receiving chemotherapy plus cetuximab (CTX). Each treatment arm was split into tertiles based on miR-31-3p expression levels. MiR-31-3p expression was also measured in LM from 94 patients with tumor tissue available. Results : The median progression-free survival for the combined populations with mid or high miR-31-3p expression was shorter in the CTX versus the CT arm (26.7 months versus 12.3 months, HR=2.28 95%CI 1.27; 4.09 p=0.006). Low miR-31-3p expressers had similar outcomes irrespective of treatment (HR=1.06 95%CI 0.43; 2.61 p=0.9). MiR-31-3p expression was correlated between paired PT and LM samples in the CT group but not in the CTX group. Conclusions : Patients with low miR-31-3p expression in the New EPOC study were not harmed by the addition of cetuximab. This supports miR-31-3p as a promising predictive biomarker for anti-EGFR therapy in KRAS WT advanced colorectal cancer.
18
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +17